ACADIA Pharmaceuticals Inc. vs Cintas Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Cintas Corporation trades at $205.28 (market cap $82.15B). The key difference: Cintas Corporation is far larger — about 16.2× ACADIA Pharmaceuticals Inc.'s market cap, and Cintas Corporation pays a 1.01% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CTAS | |
|---|---|---|
Market Cap | $5.07B | $82.15B |
Sector | Health | Industrials |
52-Week High | $29.41 | $225.10 |
52-Week Low | $20.06 | $163.55 |
Enterprise Value | $4.19B | $84.56B |
Dividend Yield | — | 1.01% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →